MXPA05013869A - Metabolito de quetiapina. - Google Patents
Metabolito de quetiapina.Info
- Publication number
- MXPA05013869A MXPA05013869A MXPA05013869A MXPA05013869A MXPA05013869A MX PA05013869 A MXPA05013869 A MX PA05013869A MX PA05013869 A MXPA05013869 A MX PA05013869A MX PA05013869 A MXPA05013869 A MX PA05013869A MX PA05013869 A MXPA05013869 A MX PA05013869A
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- pharmaceutically acceptable
- bipolar
- symptoms
- formula
- Prior art date
Links
- 239000002207 metabolite Substances 0.000 title 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical class C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 title 1
- 208000024891 symptom Diseases 0.000 abstract 3
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 2
- 230000036506 anxiety Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010001497 Agitation Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010020400 Hostility Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 238000013019 agitation Methods 0.000 abstract 1
- 208000028683 bipolar I disease Diseases 0.000 abstract 1
- 208000025307 bipolar depression Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48436503P | 2003-07-02 | 2003-07-02 | |
| PCT/GB2004/002783 WO2005002586A1 (en) | 2003-07-02 | 2004-06-28 | Metabolite of quetiapine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05013869A true MXPA05013869A (es) | 2006-02-28 |
Family
ID=33563981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05013869A MXPA05013869A (es) | 2003-07-02 | 2004-06-28 | Metabolito de quetiapina. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20050026900A1 (enExample) |
| EP (1) | EP1644005B1 (enExample) |
| JP (1) | JP2007516193A (enExample) |
| KR (1) | KR20060082037A (enExample) |
| CN (1) | CN1816339B (enExample) |
| AR (1) | AR045004A1 (enExample) |
| AT (1) | ATE477803T1 (enExample) |
| AU (1) | AU2004253334A1 (enExample) |
| BR (1) | BRPI0412127A (enExample) |
| CA (1) | CA2531284A1 (enExample) |
| DE (1) | DE602004028739D1 (enExample) |
| ES (1) | ES2349091T3 (enExample) |
| IL (1) | IL172616A0 (enExample) |
| IS (1) | IS8283A (enExample) |
| MX (1) | MXPA05013869A (enExample) |
| NO (1) | NO20060556L (enExample) |
| RU (1) | RU2005141060A (enExample) |
| TW (1) | TW200509944A (enExample) |
| UY (1) | UY28400A1 (enExample) |
| WO (1) | WO2005002586A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4414237B2 (ja) * | 2002-03-20 | 2010-02-10 | テバ ファーマシューティカル インダストリーズ リミティド | ケチアピンヘミフマレートの結晶形 |
| BRPI0417749A (pt) | 2003-12-22 | 2007-04-10 | Acadia Pharm Inc | composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas |
| WO2008021463A2 (en) * | 2006-08-15 | 2008-02-21 | Acadia Pharmaceuticals, Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| US20060081361A1 (en) * | 2004-09-13 | 2006-04-20 | Gabbey Lawrence W | Oil cooler with integral filter |
| EP1838325A1 (en) * | 2005-01-07 | 2007-10-03 | AstraZeneca AB | NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f][1,4]THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS |
| US20060252744A1 (en) * | 2005-04-04 | 2006-11-09 | Burstein Ethan S | Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents |
| JP2008502707A (ja) * | 2005-04-14 | 2008-01-31 | テバ ファーマシューティカル インダストリーズ リミティド | クエチアピンフマレートの調製方法 |
| WO2007004234A1 (en) * | 2005-07-04 | 2007-01-11 | Usv Limited | A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE |
| EP1951694A4 (en) * | 2005-11-18 | 2010-09-22 | Astrazeneca Ab | FORMS OF SALTS |
| US8389510B2 (en) | 2005-11-18 | 2013-03-05 | Astrazeneca Ab | Crystalline forms |
| WO2007062338A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Solid formulations |
| JP2009516708A (ja) * | 2005-11-18 | 2009-04-23 | アストラゼネカ・アクチエボラーグ | 液体製剤 |
| EP1951257A4 (en) * | 2005-11-18 | 2008-11-05 | Astrazeneca Ab | CRYSTALLINE FORMS |
| WO2008118141A2 (en) * | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| JP2010514682A (ja) * | 2006-12-20 | 2010-05-06 | アストラゼネカ・アクチエボラーグ | 化合物及びその使用 |
| JP2010514684A (ja) * | 2006-12-20 | 2010-05-06 | アストラゼネカ・アクチエボラーグ | 化合物及びその使用 |
| CN101616661A (zh) * | 2006-12-20 | 2009-12-30 | 阿斯利康(瑞典)有限公司 | 化合物及其用途 |
| CN101641101A (zh) * | 2007-03-22 | 2010-02-03 | 阿斯利康(瑞典)有限公司 | 治疗心境障碍的方法 |
| CN107714703A (zh) | 2009-12-31 | 2018-02-23 | 凯姆制药公司 | 喹硫平的氨基酸缀合物、其制备和使用方法 |
| RS58335B1 (sr) | 2010-03-11 | 2019-03-29 | Kempharm Inc | Konjugati kvetiapina sa masnom kiselinom, proces za njihovo dobijanje i njihova primena |
| CN102552128B (zh) * | 2012-02-28 | 2013-09-18 | 陆荣政 | 一种富马酸喹硫平注射液及其制备方法 |
| US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL140242B (nl) * | 1963-03-01 | 1973-11-15 | Wander Ag Dr A | Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen. |
| GB1192812A (en) * | 1966-05-20 | 1970-05-20 | American Cyanamid Co | 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts |
| US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| US3966949A (en) * | 1973-10-12 | 1976-06-29 | Richardson-Merrell Inc. | Pharmaceutical compositions and preparing same |
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US5750566A (en) * | 1994-08-12 | 1998-05-12 | Eli Lilly And Company | Synthetic excitatory amino acids |
| US6342488B1 (en) * | 1998-08-18 | 2002-01-29 | Sepracor, Inc. | Phosphonorisperidone and sulforisperidone compositions and methods |
| WO2004064753A2 (en) * | 2003-01-23 | 2004-08-05 | Acadia Pharmaceuticals Inc | Use of n-desmethylclozapine to treat human neuropsychiatric disease |
-
2004
- 2004-06-28 BR BRPI0412127-9A patent/BRPI0412127A/pt not_active IP Right Cessation
- 2004-06-28 JP JP2006518324A patent/JP2007516193A/ja not_active Ceased
- 2004-06-28 CA CA002531284A patent/CA2531284A1/en not_active Abandoned
- 2004-06-28 RU RU2005141060/15A patent/RU2005141060A/ru not_active Application Discontinuation
- 2004-06-28 ES ES04743131T patent/ES2349091T3/es not_active Expired - Lifetime
- 2004-06-28 WO PCT/GB2004/002783 patent/WO2005002586A1/en not_active Ceased
- 2004-06-28 CN CN2004800188710A patent/CN1816339B/zh not_active Expired - Fee Related
- 2004-06-28 EP EP04743131A patent/EP1644005B1/en not_active Expired - Lifetime
- 2004-06-28 MX MXPA05013869A patent/MXPA05013869A/es not_active Application Discontinuation
- 2004-06-28 KR KR1020057025264A patent/KR20060082037A/ko not_active Withdrawn
- 2004-06-28 DE DE602004028739T patent/DE602004028739D1/de not_active Expired - Lifetime
- 2004-06-28 AT AT04743131T patent/ATE477803T1/de not_active IP Right Cessation
- 2004-06-28 AU AU2004253334A patent/AU2004253334A1/en not_active Abandoned
- 2004-07-01 US US10/883,024 patent/US20050026900A1/en not_active Abandoned
- 2004-07-02 AR ARP040102345A patent/AR045004A1/es not_active Application Discontinuation
- 2004-07-02 UY UY28400A patent/UY28400A1/es not_active Application Discontinuation
- 2004-07-02 TW TW093120058A patent/TW200509944A/zh unknown
-
2005
- 2005-12-15 IL IL172616A patent/IL172616A0/en unknown
-
2006
- 2006-02-01 IS IS8283A patent/IS8283A/is unknown
- 2006-02-02 NO NO20060556A patent/NO20060556L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE477803T1 (de) | 2010-09-15 |
| US20050026900A1 (en) | 2005-02-03 |
| WO2005002586A1 (en) | 2005-01-13 |
| RU2005141060A (ru) | 2006-07-27 |
| IS8283A (is) | 2006-02-01 |
| CN1816339B (zh) | 2010-12-15 |
| UY28400A1 (es) | 2005-01-31 |
| KR20060082037A (ko) | 2006-07-14 |
| EP1644005B1 (en) | 2010-08-18 |
| EP1644005A1 (en) | 2006-04-12 |
| ES2349091T3 (es) | 2010-12-27 |
| AR045004A1 (es) | 2005-10-12 |
| JP2007516193A (ja) | 2007-06-21 |
| NO20060556L (no) | 2006-04-03 |
| CN1816339A (zh) | 2006-08-09 |
| TW200509944A (en) | 2005-03-16 |
| AU2004253334A1 (en) | 2005-01-13 |
| DE602004028739D1 (de) | 2010-09-30 |
| CA2531284A1 (en) | 2005-01-13 |
| WO2005002586A8 (en) | 2006-02-09 |
| IL172616A0 (en) | 2006-04-10 |
| BRPI0412127A (pt) | 2006-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005002586A8 (en) | Metabolite of quetiapine | |
| Tandon et al. | Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome | |
| WO2002053140A3 (en) | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents | |
| CY1111594T1 (el) | Μεθοδοι για τη θεραπευτικη αντιμετωπιση της ψυχωσης και της σχιζοφρενειας με βαση πολυμορφισμους στο γονιδιο του cntf | |
| IL213649A0 (en) | Prodrugs of gabapentin compounds, compositions and their use in the manufacture of a medicament | |
| WO2004019884A3 (en) | Agents and methods for enhancing bone formation | |
| MXPA05002420A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos. | |
| GB0217382D0 (en) | Process for making orally consumable dosage forms | |
| JP2007516193A5 (enExample) | ||
| GEP20074123B (en) | Amino acids with affinity for the alpha−2−delta−protein | |
| BRPI0512958A (pt) | antagonistas de nk1 | |
| BR0314299A (pt) | Derivados de pirrolidona como inibidores de mao-b | |
| EE200100136A (et) | Atsetüülkoliini esteraasi inhibiitori ja psühhoosivastase toimeaine kasutamine ravimi valmistamiseks, mis on ette nähtud kognitsiooni- ja psühhoosihäirete raviks, ning neid aineid sisaldav farmatseutiline kompositsioon | |
| BRPI0416534A (pt) | composições multiparticuladas com estabilidade melhorada | |
| DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| JO2273B1 (en) | Dihydro-benzo derivatives [B] [1.4] di-azin-2-one | |
| MXPA05013628A (es) | Pirazolo[3,4-b]piridin-6-onas como inhibidores de gsk-3. | |
| MXPA05009986A (es) | Tratamiento de la enfermedad de alzheimer. | |
| MXPA04002510A (es) | Combinacion de opioides selectos con antagonistas de muscarina para tratamiento de incontinencia urinaria. | |
| DE602004023762D1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren | |
| TWI340639B (en) | Pharmaceutical composition for treating luts, other than urinary incontinence, associated with oab and/or bph | |
| TW200735878A (en) | Pharmaceutical compositions | |
| RU2006130687A (ru) | Лечение психозов антипсихотическим агентом кветиапином | |
| WO2004082584A3 (en) | 5ht2c receptor antagonists in the treatment of schizophrenia | |
| PL1631296T3 (pl) | Pochodne amidu kwasu 2,3,4,5,-tetrahydrobenzo[f][1,4]oksazepino-5-karboksylowego jako inhibitory gamma-sekretazy do leczenia choroby Alzheimera |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |